We are a clinical-stage biotechnology company dedicated to improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia, the sentinel cells of the brain’s immune system
We are utilizing tools of modern neuroscience drug development across multiple therapeutic modalities in an effort to develop precision-based therapies
Iluzanebart, our lead clinical candidate, is a fully human monoclonal antibody agonist targeting TREM2 in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. We are also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease (AD) patients, including some who carry TREM2 and other disease-associated variants.
Building on our insights from our clinical programs, we plan to broaden our therapeutic focus into other rare and common neurodegenerative diseases also linked to microglial dysfunction.
